bioAffinity Technologies, Inc. (BIAF) - Total Liabilities
Based on the latest financial reports, bioAffinity Technologies, Inc. (BIAF) has total liabilities worth $3.68 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
bioAffinity Technologies, Inc. - Total Liabilities Trend (2019–2025)
This chart illustrates how bioAffinity Technologies, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See bioAffinity Technologies, Inc. working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
bioAffinity Technologies, Inc. Competitors by Total Liabilities
The table below lists competitors of bioAffinity Technologies, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Caledonia Mining Corporation Plc
LSE:CMCL
|
UK | GBX116.79 Million |
|
Agereh Technologies Inc
V:AUTO
|
Canada | CA$6.35 Million |
|
Adeunis
PA:ALARF
|
France | €5.38 Million |
|
Seya Industries Limited
NSE:SEYAIND
|
India | Rs7.87 Billion |
|
Enrg Elements Ltd
AU:EEL
|
Australia | AU$120.48K |
|
AS Rigas kugu buvetava
STU:UW3
|
Germany | €5.68 Million |
|
Marston’s PLC
LSE:MARS
|
UK | GBX1.53 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down bioAffinity Technologies, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BIAF stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how bioAffinity Technologies, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for bioAffinity Technologies, Inc. (2019–2025)
The table below shows the annual total liabilities of bioAffinity Technologies, Inc. from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.68 Million | -5.84% |
| 2024-12-31 | $3.91 Million | +16.20% |
| 2023-12-31 | $3.37 Million | +195.63% |
| 2022-12-31 | $1.14 Million | -93.40% |
| 2021-12-31 | $17.24 Million | +13.31% |
| 2020-12-31 | $15.22 Million | +224.19% |
| 2019-12-31 | $4.69 Million | -- |
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology t… Read more